Clinical Trials
Below are recently opened clinical trials that are currently available at Fox Chase Cancer Center. To refer a patient to any of these studies, please call 215-214-1515 or visit FoxChase.org/ClinicalTrials.
Featured Clinical Trials
Adaptive Radiation Therapy for Men with Intermediate- or High-Risk Prostate Cancer (DE-CART)
The premise of DE-CART is to use adaptive radiation to improve the efficacy of traditional prostate stereotactic body radiation therapy (SBRT). The adaptive SBRT approach will deliver prostate SBRT to the entire gland and focus an even ...
Adaptive Radiation for Abdominopelvic Metastases (ARAM) - Clinical Trial
Recent advancements in radiation technology permit daily adjustment of the radiation plan to account for changes in position of the organs in your abdomen and pelvis and variations in the surrounding normal tissues. This means a new radiation ...
Can we lower the chance of gastric cancer from growing or spreading by administering paclitaxel chemotherapy directly into the abdominal cavity in addition to chemotherapy given through a vein in the arm? Will administering paclitaxel ...
Prehabilitation in High-Risk Oncologic Surgery: A Prospective Cohort Study (PRS III)
The goal of this clinical study is to learn whether a prehabilitation program can improve recovery after major abdominal surgery in adults with cancer who are receiving treatment before surgery.
Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer
The goal of this clinical trial is to learn if Adaptive Radiation Therapy (ART) is safe and effective in treating patients with locally advanced pancreatic cancer.
Adaptive Radiation Boost for Rectal Cancer (ARBOR)
The goal of this clinical trial is to find out if giving extra adaptive radiation therapy after standard chemoradiation treatment is safe and helpful for people with rectal cancer.
This is a randomized, phase 3, multicenter trial designed to determine if induction weekly chemotherapy, when added to standard concurrent chemoradiotherapy and immunotherapy, for locally advanced cervical cancers can improve disease control ...
DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progression ...
This phase II trial studies the effect of lutetium Lu 177 dotatate compared to the usual treatment (everolimus) in treating patients with somatostatin receptor positive bronchial neuroendocrine tumors that have spread to other places in the body (advanced).
This is a multicenter randomized control trial evaluating novel BTK degrader (BGB-16673) versus standard of care pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma ...
Surgery With or Without Neoadjuvant Chemotherapy in High-Risk RetroPeritoneal Sarcoma (STRASS2)
This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyosarcoma) ...
This trial is a multi-site, single-arm, phase II trial of neoadjuvant combination of enfortumab vedotin and pembrolizumab in cisplatin-eligible patients with high-grade localized/locally advanced cT1-4 N0-1 M0 upper tract urothelial cancer ...


